(281) 713-2962
800 Rockmead Drive, Suite 155
Kingwood, TX 77339
[email protected]
A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis
Status: Recruiting
Location: Kinevant Study Site
Conditions: Kinevant Study Site
City/State:
Birmingham, Alabama
Palo Alto, California
Valencia, California
Denver, Colorado
Gainesville, Florida
Augusta, Georgia
Chicago, Illinois
Iowa City, Iowa
Kansas City, Kansas
New Orleans, Louisiana
Baltimore, Maryland
Minneapolis, Minnesota
Rochester, Minnesota
Greenville, North Carolina
Cincinnati, Ohio
Cleveland, Ohio
Philadelphia, Pennsylvania
Pittsburgh, Pennsylvania
Charleston, South Carolina
Rock Hill, South Carolina
Dallas, Texas
Houston, Texas
Charlottesville, Virginia
Falls Church, Virginia
Contact Information:
Gary Barrera
650-303-7132
[email protected]
Brief Summary:
This is a randomized, double-blind, placebo-controlled study with an open-label extension (OLE).
Detailed Description:
This is a randomized, double-blind, placebo-controlled study with an OLE.
Participants will be randomized to receive namilumab or placebo in the 26-week Double-blind Treatment Period of the study. Namilumab, or placebo, will be administered subcutaneously (SC) every 4 weeks through Week 22 after the initial dosing period.
All participants, who complete the 26-week Double-blind Treatment Period, may be eligible to participate in the 28-week OLE.
Further details are in the protocol.